In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1) pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.
In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1) pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons. [3, 4] . This same vaccine composition is being used in the upcoming northern hemisphere for the 2017/18 influenza season [5] . Here we report interim influenza vaccine effectiveness estimates for 2017 in Australia, using sentinel surveillance data.
Data collection
The Australian Sentinel Practices Research Network (ASPREN) and the Victorian Sentinel Practice Influenza Network (VicSPIN) constitute Australia's two sentinel influenza general practice (GP) networks. VicSPIN operates in the state of Victoria, while ASPREN operates nationally. Both surveillance systems use similar data collection methods [6, 7] , with the key difference that the VicSPIN surveillance period is limited to weeks 18 to 43 (1 May 1-29 October), timed to start roughly 2 weeks after vaccination campaigns in midApril. Briefly, sentinel GPs submit weekly reports of the number of patients seen with influenza-like illness (ILI), defined as fever/history of fever, cough and fatigue, and the total number of patients. Nose/ throat swabs are collected from a subset of patients with demographic data, date of ILI onset, vaccination status (self-reported or medical record) and indications for vaccination, such as belonging to an influenza risk group. Swabs are tested by RT-PCR and positive samples are referred to the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza in Melbourne, for antigenic characterisation by haemagglutination inhibition assay (HAI) [8] or focus reduction assay (FRA) [9] and genetic sequencing, as described previously [6] . All data were managed and analysed using R version 3.4.1.
Influenza-like illness activity
ILI data from ASPREN for 2017 and 2012 to 2016 (averaged) are plotted in Figure 1A and indicate consultation rates were higher in 2017 than in the previous 5 years. For the study period from 1 May 2017 to 24 September 2017, i.e. weeks 18-38, the 262 ASPREN GPs and 88 VicSPIN GPs conducted 493,961 consultations, of which 5,678 (1.1%) met the ILI case definition and swabs were collected from 2,465 (43%) of them. Influenza cases were detected in every week of the study period and peaked in week 34 (21) (22) (23) (24) (25) (26) (27) n = 235) . Percentage of positive samples peaked in week 32 (7) (8) (9) (10) (11) (12) (13) with 58%.
Virological characteristics
Virological analyses and vaccine effectiveness estimation were restricted to the period 1 May to 24 September (weeks . During this period, 2,456 patients were swabbed, but samples from 116 patients were excluded because of missing information on vaccination status, and one with missing influenza status. Among the remaining 2,339 patients, working-age adults comprised the majority (n = 1,604, 69%), 440 (19%) were aged < 15 years and 297 (13%) were aged ≥ 65 years. Around 37% (477/1,279) of test-negative patients were vaccinated in 2017.
Eighty-eight patients tested positive for A(H1)pdm09, 522 were A(H3), 75 were not yet subtyped, 11 were B/ Victoria, 259 were B/Yamagata and 105 were influenza In panel A the mean and maximum are calculated by first aligning the peaks for each season, then calculating the weekly mean and maximum consultation rate, as described in [22] .
In panel B the shaded rectangular area shows the weeks for which data were included in the vaccine effectiveness analyses, 1 May 2017 to 24 September 2017. 
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The phylogenetic tree was created using GENEiOUS, (Biomatters Limited.), Randomized Axelerated Maximum Likelihood (RAxML) Version 8, and Phylogenetic Analysis by Maximum Likelihood (PAML). Blue colouring indicates the virus came from a vaccinated patient. Red colouring indicates vaccine reference viruses. Not all viruses analysed are shown. There were 128 (62%) 3C.2a viruses, among which there were several variants when compared with the vaccine strain, A/Hong Kong/4801/2014, all but three of which included the gain of a potential glycosylation site at position 160 (K160T(+)), which distinguishes these viruses from the vaccine strain. Additional substitutions included 59 viruses characterised by substitutions at N31S,D53N,R142G,S144R,N171K,I192T, 45 by N121K,S144K, and 15 by T131K,R142K,R261Q. Seventyeight (38%) viruses were 3C.2a1 viruses, among which 13 were characterised by substitutions at N121K,G479E,T135K(-) (loss of a potential glycosylation site at position 135) and 61 by K92R,N121K,H311Q including 34 that also had T135K(-).
B, but the lineage was not yet determined ( Figure 1B ). Virus isolation was attempted for samples with a cycle threshold value of 30 or less (Table 1) . HAI testing indicated that isolates were generally antigenically similar to their respective vaccine strains. Thirty-seven percent (n=98) of A(H3) viruses yielded insufficient haemagglutinin titres for testing by HAI and were instead assessed by FRA. In HAI and FRA, 10% (7/67) and 0% (0/75) of A(H3) viruses, respectively, were low reacting to post-infection ferret antisera raised to cell-propagated A/Hong Kong/4801/2014-like viruses. However, these proportions increased to 33% (22/67) and 20% (15/75 ), respectively, when tested against egg-propagated reference virus.
Sequences for the haemagglutinin gene were available for a subset of A(H3) viruses (Figure 2) . Examination of the phylogenetic tree identified considerable diversity with a number of viruses exhibiting amino acid substitutions in key glycosylation and antigenic sites but no specific clustering of vaccine failures. GISAID accession numbers for these viruses were 271246, 271303, 275219, 275220, 275225, 275226, 275227, 275228, 275246, 275247, 275248, 275278, 275280, 277305, 277315, 277557 .
Vaccines effectiveness estimates
Vaccine effectiveness (VE) was estimated following a case-control test-negative design, where VE is estimated from the odds ratio (OR) comparing the odds of vaccination among test-positive and test-negative patients. The limitations of this design have been discussed at length [10, 11] . Estimates were adjusted for week of specimen collection (cubic spline with 4 knots), and age group (spline with knots at 5, 15, 35, 65, 75 years) .
VE estimates are shown in Table 2 . Overall VE was 33% (95%CI: 17 to 46). This estimate appeared to be skewed by the very low estimate for A(H3), which was 10% (95%CI: -16 to 31), whereas estimates were higher for A(H1)pdm09 (VE: 50%; 95%CI: 8 to 74) and B (VE: 57%; 95%CI: 41 to 69). VE for A(H3) 3C.2a viruses was 5% (95%CI: -51 to 40), while the estimate for 3C.2a1 was 19% (95%CI: -42 to 55). For patients vaccinated in the 2016 season, VE for A(H3) was 3-4% regardless of whether they were also vaccinated in 2017. In contrast, the highest VE point estimates for influenza B were observed among those vaccinated in both 2016 and 2017.
Discussion
Our interim analysis suggests moderate VE against influenza A(H1)pdm09 and influenza B. However, VE was low against influenza A(H3). The antigenic data reflect ongoing issues with A(H3) candidate vaccine viruses which, when propagated in eggs, rapidly acquire adaptive changes in the haemagglutinin which alter antigenicity. Cell-based vaccines, which are less affected by this, are only licensed in the United States, were not available in Australia in 2017 and will also not be available for the upcoming European season. The significant genetic diversity of circulating viruses, many of which exhibit amino acid substitutions in key antigenic and glycosylation sites, also makes it difficult to select candidate vaccine viruses with high coverage.
This was the second season for which the A/Hong Kong/4801/2015-containing vaccine was used in Australia [3, 12] , and campaigns currently underway in the northern hemisphere are also using it for a second time [5, 13] . During the 2016/17 northern hemisphere season interim VE estimates ranged from 15% (95%CI: -11 to 35) to 43% (95%CI: 29 to 54) [14] [15] [16] [17] . It is unclear whether sequential vaccination will result in lower estimates for 2017/18, but our VE estimates were particularly low for people who received vaccine in 2016 and for older adults, 76% of whom were sequentially vaccinated. This finding is consistent with a modelling study which predicts low VE for sequentially vaccinated persons when the vaccine composition is identical, but the antigenic distance between the vaccine and circulating strains is high [18] . However, confounding due to prior infection status and negative interference from pre-2016 vaccines could not be controlled for in our analysis, and may have introduced bias.
In contrast to A(H3), VE estimates for influenza B were moderate and the combined effects of vaccination in 2016 and 2017 did not blunt effectiveness for influenza B, even though the composition remained the same. Similarly, VE for the few A(H1)pdm09 cases recruited was moderate, although low for Australia at 50% (95%CI: 8 to 74), where VEs have ranged from 54% to 79% in the past [6, 7] . This was the one component of the 2017 vaccine that was updated since 2016, from A/ California/7/2009 to A/Michigan/45/2015.
This study provides interim estimates of the 2017 southern hemisphere influenza vaccine in the outpatient setting and may not apply to inpatient settings or severe illness. Interim estimates can reliably predict final season estimates [19] , particularly when made after the peak [20] , as is the case here. Should the circulating A(H3) influenza viruses predominate in the 2017/18 northern hemisphere influenza season [21] , our results suggest that the vaccine may confer limited protection. Health authorities should consider other influenza prevention measures, including antivirals and health promotion messaging, in the event of a severe season and low VE against A(H3).
